Reuters logo
BRIEF-Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures
December 7, 2016 / 12:25 PM / in 10 months

BRIEF-Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures

Dec 7 (Reuters) - Abiomed Inc

* Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below